Get the Stockscreener App
0.484
1.87%
0.0089
After Hours:
.46
-0.024
-4.96%
Windtree Therapeutics Inc stock is traded at $0.484, with a volume of 415.13K.
It is up +1.87% in the last 24 hours and down -47.01% over the past month.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
See More
Previous Close:
$0.4751
Open:
$0.499
24h Volume:
415.13K
Relative Volume:
0.25
Market Cap:
$4.20M
Revenue:
-
Net Income/Loss:
$-11.38M
P/E Ratio:
-0.0187
EPS:
-25.91
Net Cash Flow:
$-12.72M
1W Performance:
-19.33%
1M Performance:
-47.01%
6M Performance:
-89.22%
1Y Performance:
-48.51%
1-Day Range:
$0.46
$0.50
1-Week Range:
$0.4515
$0.62
52-Week Range:
$0.2654
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
(215) 488-9300
Address
2600 KELLY ROAD, WARRINGTON, PA
Compare WINT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| WINT | 0.484 | 4.20M | 0 | -11.38M | -12.72M | -25.91 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
Windtree Therapeutics CEO to retire with company's future in doubt - The Business Journals
Leadership Transition at Windtree Therapeutics: Fraser Retires, Latkin Takes Helm - MyChesCo
Windtree Therapeutics Announces CEO Transition and Appointment of New Chief Executive Officer - Defense World
ARMISTICE CAPITAL, LLC Acquires New Stake in Windtree Therapeuti - GuruFocus.com
Windtree Therapeutics Appoints Jed Latkin as New CEO - TipRanks
Windtree Therapeutics announces CEO Fraser to retire, Latkin to succeed - TipRanks
Windtree Therapeutics announces CEO transition - Investing.com
Windtree Announces Leadership Transition Plan With Industry Veterans - GlobeNewswire
Windtree Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective December 1, 2024 - Marketscreener.com
WINT Stock Hits 52-Week Low at $0.53 Amid Steep Decline - Investing.com
WINT: Patient Enrollment in SEISMiC C Trial Starts, Patent Position Expands - Yahoo Finance
Windtree Therapeutics Secures Hong Kong Patent for Istaroxime in Heart Failure Treatment - MSN
WINT stock touches 52-week low at $0.62 amid sharp annual decline - Investing.com
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic Shock - MSN
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong - GlobeNewswire
Windtree Therapeutics Initiates SEISMiC C Study of - GlobeNewswire
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 - The Manila Times
Windtree Therapeutics Secures Global Patent Filings for Istaroxime - MSN
Windtree Therapeutics announces $27.24 million equity sale option - Investing.com India
Windtree Therapeutics announces $27.24 million equity sale option By Investing.com - Investing.com UK
Windtree Therapeutics Prepares to Highlight Istaroxime Progress at ThinkEquity Conference - MSN
Windtree Therapeutics completes national phase filings for istaroxime - Yahoo Finance
Windtree Therapeutics advances global patent filings for shock therapy - Investing.com
Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World - GlobeNewswire
Windtree To Present at the ThinkEquity Conference on October 30th - GlobeNewswire
Reviewing Windtree Therapeutics (NASDAQ:WINT) and INmune Bio (NASDAQ:INMB) - Defense World
Windtree Therapeutics Secures Patent for Heart Failure Treatment in Japan - MSN
Windtree Therapeutics secures Japan patent for heart drug - Investing.com
Windtree Therapeutics secures Japan patent for heart drug By Investing.com - Investing.com Australia
Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan - The Manila Times
A significant driver of top-line growth: Windtree Therapeutics Inc (WINT) - SETE News
Windtree Therapeutics Inc (WINT) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Recent Insider Activity Suggests Potential Gains for Windtree Therapeutics Inc (WINT) - Knox Daily
Was Windtree Therapeutics Inc (WINT)’s session last reading good? - US Post News
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected Milestones - Research Tree
Windtree Therapeutics Publishes SEISMiC Phase 2b Trial Design for Cardiac Treatment - MSN
Ladenburg Thalmann slashes price target on Windtree Therapeutics Inc [WINT] – find out why. - The DBT News
Windtree Therapeutics CEO buys $4.9k in company stock - Investing.com India
Windtree Therapeutics advances Phase 2b cardiogenic shock study By Investing.com - Investing.com Australia
Windtree Therapeutics CEO buys $4.9k in company stock By Investing.com - Investing.com Australia
WINT’s Stock Journey: What Investors Need to Know About Windtree Therapeutics Inc’s Performance - The InvestChronicle
Windtree Therapeutics advances Phase 2b cardiogenic shock study - Investing.com India
Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design - The Manila Times
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.66%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):